CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...

Because poor adherence to GLP-1 receptor agonists may limit the long ... Saxenda), semaglutide (Ozempic, Wegovy), or tirzepatide (Mounjaro, Zepbound) -- all of which hold indications for type ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known as GLP-1s, are changing how Americans shop for groceries. In early January, Food & Wine published a story about ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...